VERI/O Laboratory Services

VERI/O Laboratory Services support biopharma clients and collaborators in biomarker research and companion diagnostic development. In addition to service offerings based on HTG’s currently marketed products, we plan to offer services using our new technologies and profiling panels as they become available.  One assay now available is the HTG EdgeSeq EGFR, KRAS, and BRAF Mutation Assay.  This assay is a research use only (RUO) service offering exclusively available in the VERI/O Laboratory.  Potential applications with this assay include the use of a prepared lysate from a single FFPE tissue section to generate a comprehensive molecular profile including gene expression, gene rearrangements, and DNA mutations.  

"The VERI/O Laboratory will support biopharma’s translational and early stage clinical biomarker development.  We already have seen success deploying this model with our biopharma clients, enabling us to closely partner with them to meet the needs of their drug development programs." - TJ Johnson, HTG President & CEO


  • Profiling of retrospective cohorts to support development of targeted and immuno-oncology therapies
  • Developing custom research-use-only (RUO) assays to support early stage clinical programs
  • Developing investigational-use-only (IUO) assays for use in Phase II/III registration trials
  • Obtaining regulatory clearances and worldwide commercialization of companion diagnostic as in vitro diagnostic (IVD) assays

Service Offerings

Below are the VERI/O Laboratory offerings contrasted with the products available for use on the HTG EdgeSeq system.

Applications in Immuno-Oncology


Features Benefits

Tumor Microenvironment

  • Measure the gene expression of microdissected tumor subsections such as vasculature, stroma, and tumor from a single FFPE tissue section
  • Develop insights into the tumor biology
    • Tumor infiltrating lymphocyte (TIL) composition and density
    • Interferon gamma expression levels
    • T-cell effector status
    • Cytokine expression
    • Immunomodulation


  • Simultaneous monitoring of multiple chemokines and cytokines within cancer tissue and associated stroma
  • Spatial-temporal mapping of immune-stimulatory or suppressant signals

Resistance / Relapse System Biology

  • Characterization of pathway modulators that impact cancer drug response
  • Better understanding of how disease progression is tied to underlying tumor biology
  • Investigate alternative clinically actionable drug targets for late stage cancer patients


  • Measure the expression of cytokeratins, clusters of differentiation, epithelial genes and other histological markers
  • Identify or confirm histological grading of critical specimens
  • Sub-classify cancers into subtypes

Signaling Pathways

  • Assess the status of pathways such as:
    • Angiogenesis/vasculature
    • Apoptosis
    • Epithelial-mesenchymal transition
    • Stem cell markers
  • Grouping tumors via common dysregulated molecular pathways can provide deeper molecular understanding of tumors


More Applications

Applications Features Benefits

Immune checkpoint expression within molecular subtyped diffuse large B-cell (DLBCL) tumors

  • Characterization of immunocheckpoint factors together with tumor infiltrating lymphocyte (TIL) markers within DLBCL tumors classified via subtype
  • Investigate tumor immune-responsiveness of DLBCL tumors
miRNA profiling of tumors and blood
  • Identify tumor miRNA-based signatures from different sample types using whole transcriptome miRNA profiling
  • Identify tissue-based miRNA profiles that can be translated to blood samples

Immunophenotyping immune cells

  • Pseudo-flow analysis using CD-based markers
  • Sensitivity and ability to multiplex above applications/markers
Subtyping DLBCL Tumors
  • Characterize cases as Activated B-Cell Type (ABC) vs. Germinal Center B-Cell Type (GCB)
  • Stratify groups for biomarker and drug development


Sample Types and Input Requirements


More information on our panels and assays available through VERI/O Laboratory Services

Oncology Biomarker Panel
2,560 key tumor biomarkers

Immuno-Oncology Assay
549 key tumor immune response genes

miRNA Whole Transcriptome Assay
2,083 human miRNA transcripts

DLBCL Cell of Origin Assay RUO
Subtype DLBCL tumors, lineage markers

PATH Assay

ALKPlus Assay EU (CE IVD)

ALKPlus Assay RUO Content Guide

EGFR, KRAS, and BRAF Mutation Assay
With just a 5 µm FFPE tissue section, obtain gene expression, fusion and mutation status


Ready to get started?

Call us at 877.289.2615


For Research Use Only. Not for use in diagnostic procedures.



Last updated: 08/07/2017 - 09:14